Taking a three-drug regimen during pregnancy is the preferred option in preventing mother-to-child HIV transmission a study has found. The ongoing PROMISE study (Promoting Maternal-Infant Survival Everywhere) aims to determine how best to safely reduce the risk of HIV transmission from infected women to their babies during pregnancy and post-delivery.
In comparing two proven strategies, researchers discovered giving women a triple drug regimen throughout the pregnancy and delivery was more effective than giving women zidovudine during the pregnancy, a single dose of nevirapine during labor, and two weeks of tenofovir and emtricitabine after delivery.
“We now have a gold standard of evidence — data from a randomised clinical trial,” said Anthony S. Fauci of the US National Institutes of Health. “This is another important step in our efforts to define the best approaches toward the goal of eliminating mother-to-child HIV transmission globally.”